Key Details of UPSC NDA & NA 1 Exam 2025

• Exam Date: April 13, 2025
• Total Seats: 406 vacancies
  • National Defence Academy
    • Army: 208 (10 for female candidates)
    • Navy: 42 (6 for female candidates)
    • Air Force (Flying Branch): 92 (2 for female candidates)
    • Air Force (Ground Duties – Tech): 18 (2 for female candidates)
    • Air Force (Ground Duties – Non-Tech): 10 (2 for female candidates)
  • Naval Academy
    • 38 seats

Eligibility Criteria for UPSC NDA and NA 1 Exam 2025

1. Age Limit

• born in the period from July 2, 2006, to July 1, 2009.
• Only unmarried male and female candidates are eligible.

2. Educational Qualification

• For Army Wing: Must have passed Class 12 or equivalent from a recognized board.
• For Air Force and Naval Wings: Must have passed Class 12 with Physics, Chemistry, and Mathematics.

Required Documents for UPSC NDA and NA 1 Exam 2025

Candidates must have the following documents ready in PDF format for the application process:

1. Visit the official UPSC website: upsc.gov.in.
2. Click on the “NDA I Application Form” link.
3. Complete Part I of the application for registration.
4. Log in with your registration details to fill out Part II.
5. Submit the required files and pay the application fee.
6. Submit the form and save a copy for future your reference.

Important Dates for UPSC NDA and NA 1 Exam 2025

Application Correction Window

Candidates who register for UPSC NDA and NA 1 Exam 2025 within the deadline can make corrections to their applications between January 1 and January 7, 2025.

Also Read: MPPSC Results 2023 Declared: Check State Service Mains Exam Results at mppsc.mp.gov.in

Exam Openings and Selection

The UPSC NDA & NA 1 Exam 2025 will recruit candidates for 406 positions, while the CDS I Exam 2025 will fill 457 vacancies. These figures may change based on the training capacities of the National Defence Academy and Indian Naval Academy.

Aspiring candidates are encouraged to complete their registrations promptly for this prestigious opportunity. For more information, visit the official UPSC website.

This innovative hydrogel-based therapy delivers anti-cancer drugs directly to tumor sites, significantly reducing the side effects typically associated with conventional cancer treatments.

The paper is co-authored by Prof. Debapratim Das, along with his research scholars Ms. Tanushree Das and Ms. Ritvika Kushwaha from IIT Guwahati, and collaborators Dr. Kuldip Jana, Mr. Satyajit Halder, and Mr. Anup Kumar Misra from Bose Institute Kolkata.

Surgical removal of tumors is sometimes not feasible, particularly for internal organs, while chemotherapy’s systemic delivery often results in harmful side effects by affecting both cancerous and healthy cells.

Design

Prof. Debpratim Das, Department of Chemistry, and his team at IIT Guwahati addressed these challenges by designing a hydrogel that delivers drugs precisely to the tumor site, ensuring localized action.

Water-based

Hydrogels are water-based, three-dimensional polymer networks capable of absorbing and retaining fluids. Their unique structure mimics living tissues, making them suitable for biomedical applications.

This newly developed hydrogel acts as a stable reservoir for anti-cancer drugs and releases them in a controlled manner, responding to specific conditions in the tumor microenvironment, say researchers from IIT Guwahati.

It responds to elevated glutathione (GSH) levels, a molecule abundant in tumor cells.

Upon encountering high GSH levels, the hydrogel triggers a controlled drug release directly into the tumor, minimizing its interaction with healthy tissues and reducing systemic side effects, say sources from IIT Guwahati.

Department of Chemistry at IIT Guwahati

Speaking about the breakthrough, Prof. Debapratim Das, Dept. of Chemistry, IIT Guwahati, said, “This work exemplifies how scientific innovation can directly address the pressing needs of cancer treatment.

The hydrogel’s unique properties allow it to work in harmony with the biological environment, offering precision where it is needed most, said Prof Debapratim Das of IIT Guwahati.

We are excited by its potential to transform our thoughts about localized drug delivery, he said.

Preclinical trials

In preclinical trials on a murine model of breast cancer, the hydrogel showcased remarkable efficacy.

A single injection of the hydrogel, loaded with the chemotherapy drug Doxorubicin, resulted in a ~75% reduction in tumor size within 18 days.

Crucially, the hydrogel remained localized at the tumor site, steadily releasing the drug over time without causing detectable side effects on other organs.

Delivery system

This innovative delivery system enhances the drug’s effectiveness while reducing the required dosage, thus minimizing toxicity.

Laboratory studies further demonstrated that the hydrogel improves drug uptake by cancer cells, induces cell cycle arrest, and promotes programmed cell death, thereby attacking tumors on multiple fronts.

Further studies

Further studies are going on to find out the maximum amount of reduction in the size of the tumor by a single dose. Moreover, we are also looking into other types of tumors, say sources from IIT Guwahati.

Once all the studies are complete, will apply to take the material for clinical trial and are looking for an appropriate partner to do the same.

At present, the Institute has eleven departments, nine interdisciplinary academic centres and five schools.

They are covering all the major engineering, science, healthcare, management, and humanities disciplines, offering BTech, BDes, BSc(Hons), MA, MDes, MTech, MSc, MS(R), MBA and PhD programmes.

The institute offers a residential campus to 455 faculty members and more than 8,600 students at present.

Also Read – IIT Madras launches great research center